All In Biotech

Drug Trial Radar · NCT01656434

Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)

A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 Years

Last checked: Nov 19, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,173 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,173

Actual

Start

Nov 2, 2012

Primary completion

Feb 12, 2014

Study completion Feb 12, 2014

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the contraceptive efficacy of a nomegestrol acetate + 17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active American women at risk for pregnancy. Vaginal bleeding patterns of women taking NOMAC-E2 were assessed and compared to those of women taking a norethisterone acetate + ethinyl estradiol (NETA-EE) COC. The safety of NOMAC-E2 was also assessed. Participants were randomized to receive either NOMAC-E2 or NETA-EE in a 3:1 ratio. As of Amendment 1 (which increased the sample size of the NOMAC-E2 group), the randomization ratio was adapted accordingly for participants randomized after the sample size increase.

Conditions

  • Contraception

Interventions

  • NOMAC-E2Drug

    NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.

  • NETA-EEDrug

    NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.

  • PlaceboOther

    tablet

  • ethinylestradiol (EE)Drug

    EE 10 μg tablet

  • ferrous fumarateDrug

    ferrous fumarate 75 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of In-Treatment Pregnancies Per 100 Woman Years of Exposure (Pearl Index)Time frame: Up to 1 year (13 cycles)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.